Search Results

You are looking at 81 - 90 of 196 items for :

  • Refine by Access: All x
Clear All
Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

GCSFs might be considered in patients with severe neutropenic fever after chemotherapy. HBV Reactivation: HBV reactivation leading to fulminant hepatitis, hepatic failure, and death have been reported in patients receiving chemotherapy and

Full access

Jeffrey A. Gilreath, David D. Stenehjem, and George M. Rodgers

be given in 1 to 4 injections for children with iron-deficiency anemia. This method was appealing to clinicians because the reported incidence of reactions was on the order of only 1% and included symptoms such as fever, arthralgia, and

Full access

cancer survivors between time points and distress the areas of eating ( P <.04), fatigue ( P <.01), fevers ( P <.02), getting around ( P <.05), mouth sores ( P <.05), congestion ( P <.02), sleep ( P <.02), fears ( P =.05), nervousness ( P =.04), physical

Full access

Michael Angarone and Michael G. Ison

transplantation: analysis of factors associated with infection . Oral Surg Oral Med Oral Pathol 1990 ; 70 : 286 – 293 . 60. Bergmann OJ Mogensen SC Ellermann-Eriksen S Ellegaard J . Acyclovir prophylaxis and fever during remission-induction therapy

Full access

Nora Janjan

be better for other physical symptoms, such as fever, and the absence of a symptom. 22 , 23 Data capture of PROs enables health care providers to evaluate the adequacy of CRP control, especially that of breakthrough pain, for individual patients

Full access

Nisha Rao, Hans Iwenofu, Bingfeng Tang, Jennifer Woyach, and David A. Liebner

for <5% of all cases. 2 IMTs most often present with signs and symptoms restricted to the areas affected; however, 15% to 30% of people present with fever, weight loss, malaise, microcytic anemia, elevated erythrocyte sedimentation rate

Full access

Karam Khaddour, Michael R. Chicoine, Jiayi Huang, Sonika Dahiya, and George Ansstas

reduction. The treatment course with trametinib and dabrafenib continued for a total of 9 months. The patient experienced mild pyrexia (grade I fever according to CTCAE version 5.0.), which required treatment interruption for 4 days before later resuming the

Full access

Robert E. Smith Jr.

first-line treatment in advanced colorectal cancer . J Clin Oncol 2000 ; 18 : 2938 – 2947 . 67. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients

Full access

Matthew Ulrickson, Fred Okuku, Victoria Walusansa, Oliver Press, Sam Kalungi, David Wu, Fred Kambugu, Corey Casper, and Jackson Orem

Mulago Hospital reporting a 7-year history of gradually increasing pruritus and diffuse, scaly skin lesions ( Figure 1A ). More recently he reported mild weight loss and anorexia, although he denied having drenching night-sweats or fevers. He denied any

Full access

Stacey Shiovitz and Keith D. Eaton

Case Report A 66-year-old woman presented with newly diagnosed stage IV non–small cell lung cancer (NSCLC) and a large adrenal metastasis. Five weeks before presentation, she developed low-grade fevers and shortness of breath with minimal